Circulating microRNA is a biomarker of pediatric crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 1, 2011, Pages 26-33

  Zahm, Adam M ^a   Thayu, Meena ^a   Hand, Nicholas J ^a   Horner, Amber ^a   Leonard, Mary B ^b   Friedman, Joshua R ^a  

^a Div of Gastroenterol and Nutrition   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

biomarker; circulating miRNA; Crohn disease

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CELIAC DISEASE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HUMAN; MALE; MICROFLUIDIC ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CHILD; CROHN DISEASE; DOWN-REGULATION; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 79959852640     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31822200cc     Document Type: Article

References (72)

1. Dotan I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Exp Rev Gastroenterol Hepatol 2007;1:265-74.
2. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:449-54.
3. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti- Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4. (Pubitemid 32240723)
4. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91. (Pubitemid 28277217)
5. Dubinsky M. What is the role of serological markers in IBD? Pediatric and adult data. Dig Dis 2009;27:259-68.
6. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-33. (Pubitemid 32193179)
7. Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19-35.
8. Anand V, Russell AS, Tsuyuki R, et al. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol 2008;22:33-6. (Pubitemid 351385649)
9. Desplat-Jego S, Johanet C, Escande A, et al. Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 2007;13:2312-8. (Pubitemid 46860731)
10. Olives JP, Breton A, Hugot JP, et al. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value. J Pediatr Gastroenterol Nutr 1997;25:142-8. (Pubitemid 27311375)
11. Proujansky R, Fawcett PT, Gibney KM, et al. Examination of antineutrophil cytoplasmic antibodies in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;17:193-7. (Pubitemid 23249801)
12. Damoiseaux JG, Bouten B, Linders AM, et al. Diagnostic value of anti- Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol 2002;22:281-8. (Pubitemid 35178823)
13. Freeman HJ. Perinuclear antineutrophil cytoplasmic antibodies in collagenous or lymphocytic colitis with or without celiac disease. Can J Gastroenterol 1997;11:417-20. (Pubitemid 27359086)
14. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354-5.
15. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation-and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14:409-12. (Pubitemid 34439041)
16. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44: 414-22. (Pubitemid 46573222)
17. Pfefferkorn MD, Boone JH, Nguyen JT, et al. Utility of fecal lactoferrin in identifying Crohn disease activity in children. J Pediatr Gastroenterol Nutr 2010;51:425-8.
18. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasivemarkers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009;48:48-54.
19. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60. (Pubitemid 34827189)
20. Wang Y, Russell I, Chen C. MicroRNA and stem cell regulation. Curr Opin Mol Ther 2009;11:292-8.
21. Vasilatou D Papageorgiou S, Pappa V, et al. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010;84:1-16.
22. Cai B, Pan Z, and Lu Y. The roles of microRNAs in heart diseases: a novel important regulator. Curr Med Chem 2010;17:407-11.
23. Fineberg SK, Kosik KS, Davidson BL. MicroRNAs potentiate neural development. Neuron 2009;64:303-9.
24. Yi R, Fuchs E. MicroRNA-mediated control in the skin. Cell Death Differ 2010;17:229-35.
25. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56.
26. Pandey AK, Agarwal P, Kaur K, et al. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 2009;23:221-32.
27. Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 2009;32:199-206.
28. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol 2009;6:419-29.
29. Kato M, Arce L, Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 2009;4:1255-66.
30. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32:189-94.
31. McKenna LB, Schug J, Vourekas A, et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010;39:654-1664. 1664 e1651.
32. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a micro- RNA expression analysis. Lancet Oncol 2010;11:136-46.
33. Slaby O, Svoboda M, Michalek J, et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009;8:102.
34. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008;35:624-35. e1624.
35. Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 2010;16:1729-38.
36. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
37. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
38. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010;391:73-7.
39. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010;31:659-66.
40. Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-90. (Pubitemid 351348154)
41. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106:4402-7.
42. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
43. Kong X, Du Y, Wang G, et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 2011;56:602-9.
44. Silva J, García V, Zaballos A, et al. Vesicle-related microRNAs in plasma of NSCLC patients and correlation with survival. Eur Respir J 2011;37:617-23.
45. Ng EK, ChongWW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
46. Wu F, Guo NJ, Tian H, et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2011;17:241-50.
47. Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 2010;139:430-8.
48. Thayu M, Shults J, Burnham JM, et al. Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2007;13:1121-8. (Pubitemid 47402596)
49. Dubner SE, Shults J, Baldassano J, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009;136:123-30.
50. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53. (Pubitemid 43764536)
51. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
52. Suh MR, Lee Y, Kim JY, et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004;270:488-98. (Pubitemid 38748567)
53. Pavlidis P, Noble WS. Matrix2png: a utility for visualizing matrix data. Bioinformatics 2003;19:295-6. (Pubitemid 36181920)
54. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. (Pubitemid 32397092)
55. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33. (Pubitemid 40839734)
56. Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009;136:1689-700.
57. Uren AG, Kool J, Matentzoglu K, et al. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 2008;133:727-41. (Pubitemid 351637624)
58. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of MicroRNAs in young stroke patients. PLoS One 2009;4: e7689.
59. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106:4402-7.
60. Cekaite L, Clancy T, Sioud M. Increased miR-21 expression during human monocyte differentiation into DCs. Front Biosci (Elite Ed) 2010;2:818-28.
61. Silva MA, Lopez CB, Riverin F, et al. Characterization and distribution of colonic dendritic cells in Crohn's disease. Inflamm Bowel Dis 2004;10:504-12. (Pubitemid 39276456)
62. Davidson LA, Wang N, Shah MS, et al. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009;30:2077-84.
63. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9. (Pubitemid 28452928)
64. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447-52. (Pubitemid 30180626)
65. Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 2007;19:e193-9. (Pubitemid 46397825)
66. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5- aminosalicylic acid treatment. Am J Gastroenterol 2003;98: 2226-31. (Pubitemid 37305363)
67. Desir B, Amre DK, Lu SE, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004;2:139-46. (Pubitemid 38180468)
68. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissuespecific microRNAs from mouse. Curr Biol 2002;12:735-9.
69. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
70. Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009;14: 529-38.
71. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004;20:167-72. (Pubitemid 38998214)
72. Efthymiou A, Viazis N, Mantzaris G, et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008;14:1542-7.